Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Certain Myasthenia Gravis Patients May Need More Time to Respond to Efgartigimod

(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to show efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, according to open-label data from...

Certain Myasthenia Gravis Patients May Need More Time to Respond to Efgartigimod

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

Are coronary stents necessary?

There is a crucial distinction between stenting as a life-saving measure to medical treatment via stenting because a narrowing of blood vessels is seen on an angiogram

More from Tuesday 27 October →